Ernexa Therapeutics Inc. Proceeds from Warrant Exercises
Ernexa Therapeutics Inc. (ERNA) reported Proceeds from Warrant Exercises of $20.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromWarrantExercises · last filed 2026-08-06
- Ernexa Therapeutics Inc. proceeds from warrant exercises for the quarter ending 2026-06-30 was $0.00.
- Ernexa Therapeutics Inc. proceeds from warrant exercises for the quarter ending 2026-03-31 was $20.00K, a 400.00% increase year-over-year.
- Ernexa Therapeutics Inc. proceeds from warrant exercises for the quarter ending 2025-12-31 was $0.00.
- Ernexa Therapeutics Inc. proceeds from warrant exercises for the quarter ending 2025-09-30 was $26.00K.
- Ernexa Therapeutics Inc. proceeds from warrant exercises for fiscal 2025 was $30.00K.
- Ernexa Therapeutics Inc. proceeds from warrant exercises for fiscal 2022 was $867.00K.
| Period end | Proceeds from Warrant Exercises 3 month | Proceeds from Warrant Exercises 6 month | Proceeds from Warrant Exercises 9 month | Proceeds from Warrant Exercises 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $20.00K 10-Q · filed 2026-08-06 | $20.00K derived: sum of 3 quarters · filed 2026-08-06 | $46.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $20.00K 10-Q · filed 2026-05-11 | $20.00K derived: sum of 2 quarters · filed 2026-05-11 | $46.00K derived: sum of 3 quarters · filed 2026-05-11 | $46.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $26.00K derived: sum of 2 quarters · filed 2026-03-13 | $26.00K derived: sum of 3 quarters · filed 2026-08-06 | $30.00K 10-K · filed 2026-03-13 |
| 2025-09-30 | $26.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $26.00K derived: sum of 2 quarters · filed 2026-08-06 | $30.00K 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $4.00K 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $4.00K 10-Q · filed 2026-05-11 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $867.00K 10-K · filed 2023-03-20 | ||
| 2022-09-30 | $867.00K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |